UNITED THERAPEUTICS Corp

Pharmaceutical Preparations·SILVER SPRING, MD·FY end 12/31·CIK 1082554

CEO Pay Ratio

76:1

Martine Rothblatt

CEO Total Comp

$55.9K

Martine Rothblatt

Median Employee

$237,406

Revenue

$3.2B

FY 2025

Net Income

$1.3B

FY 2025

Free Cash Flow

$1.0B

FY 2025

Net Margin

41.9%

Insider Net (180d)

0 buys / 0 sales

CEO Pay Accountability

CEO comp as % of net income

0.00%

For every $1,000 of profit, $0.04 flows to the CEO.

CEO comp as % of buybacks

0.01%

CEO comp equals 0.1‰ of cash returned to shareholders via buybacks.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$3.2B	$2.9B	$2.3B	$1.9B	$1.7B
Gross Profit	$2.8B	$2.6B	$2.1B	$1.8B	$1.6B
Operating Income	$1.5B	$1.4B	$1.2B	$979.7M	$555.9M
Net Income	$1.3B	$1.2B	$984.8M	—	—
Operating CF	$1.6B	$1.3B	$978.0M	$802.5M	$598.2M
Capex	$520.5M	$246.5M	$230.4M	$138.8M	$120.8M
Free Cash Flow	$1.0B	$1.1B	$747.6M	$663.7M	$477.4M
Buybacks	$1.0B	$1.0B	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	87.9%	89.2%	88.9%	92.2%	92.7%
Operating Margin	46.9%	47.9%	50.9%	50.6%	33.0%
Net Margin	41.9%	41.5%	42.3%	—	—
FCF Margin	32.7%	37.6%	32.1%	34.3%	28.3%
R&D / Revenue	17.3%	16.7%	17.5%	16.7%	32.0%
Effective Tax	22.1%	22.3%	22.7%	23.5%	19.9%
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	96.1%	92.5%	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Michael BenkowitzPresident and Chief Operating Officer	$1.4M	—	—	$3.1M	$6.4M	$3.3M
James EdgemondChief Financial Officer and Treasurer	$955.8K	—	—	$2.0M	$3.6M	$1.8M
Martine RothblattChairperson and Chief Executive Officer	$1.5M	—	—	$6.1M	$10.4M	$55.9K
Paul MahonExecutive Vice President and General Counsel	$964.2K	—	—	$1.5M	$3.0M	—